News Releases
- Chugai and Araris Biotech AG Enter License Agreement for Araris' Linker-Payload ADC Technology AraLinQ®
- NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period
- Chugai Announces 2025 Full Year Results and Forecasts for 2026
Science and Technology
Science and Technology
Careers at Chugai
Careers at Chugai
Videos
CPR celebrates 10th Anniversary